Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
作者信息
Vanchieri Cori
出版信息
J Natl Cancer Inst. 2005 Apr 20;97(8):552-3. doi: 10.1093/jnci/97.8.552.
PMID:15840872
Abstract
摘要
相似文献
1
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
J Natl Cancer Inst. 2005 Apr 20;97(8):552-3. doi: 10.1093/jnci/97.8.552.
2
COX-2 inhibitors--a lesson in unexpected problems.环氧化酶-2抑制剂——一个有关意外问题的教训。
N Engl J Med. 2005 Mar 17;352(11):1131-2. doi: 10.1056/NEJMe058038. Epub 2005 Feb 15.
3
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.药品市场中的监管家长主义：来自万络和西乐葆的教训。
Yale J Health Policy Law Ethics. 2005 Summer;5(2):741-70.
4
The COX-2 inhibitors--an update.环氧化酶-2抑制剂——最新进展
Am Heart J. 2006 Aug;152(2):197-9. doi: 10.1016/j.ahj.2006.05.022.
5
COX-2 inhibitors: no pain, no heart gain?环氧化酶-2抑制剂：无痛，无心脏获益？
Harv Heart Lett. 2001 Dec;12(4):2-4.
6
Celecoxib: a COX-2 inhibitor.塞来昔布：一种环氧化酶-2抑制剂。
Am J Manag Care. 1999 Apr;5(4):511-8; quiz 522-4.
7
[Cyclooxygenase 2 inhibitors and lung carcinoma].[环氧化酶2抑制剂与肺癌]
Bull Cancer. 2004 May;91 Suppl 2:S109-12.
8
9
The cox-2 inhibitors.环氧化酶-2抑制剂
J Mass Dent Soc. 1999 Fall;48(3):43-4.
10
[New anti-inflammatory analgetics--are they needed?].[新型抗炎镇痛药——有必要研发吗？]
Duodecim. 1999;115(20):2217-24.
引用本文的文献
1
The 50-Year War on Cancer Revisited: Should We Continue to Fight the Enemy Within?重访抗癌50年之战：我们是否应继续对抗体内之敌？
J Cancer Prev. 2021 Dec 30;26(4):219-223. doi: 10.15430/JCP.2021.26.4.219.
Zotero 插件